Journal: Drug Design, Development and Therapy
Article Title: Diallyl Disulfide Mitigates LPS-Induced Inhibition of Osteogenic Differentiation and Alleviates Inflammatory Bone Loss via PI3K/AKT Signaling Pathway
doi: 10.2147/DDDT.S590959
Figure Lengend Snippet: DADS rescues LPS-induced inhibition of osteogenic differentiation by activating the PI3K/AKT signaling pathway. ( A ) Representative images of ALP staining (scale bar = 100 μm). ( B ) ALP activity evaluation after 7 days of osteogenic induction. ( C ) Representative images of Alizarin Red staining after 14 days of osteogenic induction (scale bar = 100 μm). ( D ) Quantitative assessment of the calcium deposition in ( C ). ( E – H ) The expression of osteogenic-specific genes COL1A1, RUNX2, ALP, and OCN after 7 days of osteogenic induction. ( I – K ) Western blot and quantitative analysis of the levels of osteogenic markers COL1A1 and RUNX2 after 7 days of osteogenic induction, with total protein serving as a loading control. Statistical analysis was performed using one-way ANOVA. Data are presented as mean ± SD, n = 5 independent biological replicates per group. Exact P values for pairwise comparisons are shown above the horizontal lines; P < 0.001 denotes values below three-decimal precision.
Article Snippet: Furthermore, when validating the mechanism related to the PI3K/AKT signaling pathway, 10 μM PI3K inhibitor LY294002 (MedChemExpress, Shanghai, China) was added to the LPS+DADS high-dose group.
Techniques: Inhibition, Staining, Activity Assay, Expressing, Western Blot, Control